Abrocitinib is the first-of-its-kind oral advanced systemic treatment for adults with moderate-to-severe atopic dermatitis, to be made available in India. Abrocitinib provides rapid itch relief, sustained control of the disease and improved quality of life. Pfizer has received marketing authorization for abrocitinib in adults